Prognostic role of microRNA-203 in various carcinomas: evidence from a meta-analysis involving 13 studies

SpringerPlus

Table 1 Characteristics of studies included in the meta-analysis

First author	Years	Country	Gender Male/female	Median age (years)	Disease	Number	Stage I–II/III–IV	miR-203 assay	Source of HR	Maximum months of follow-up
Chen	2012	China	56/10	56 (40–73)	Hepatocellular	66	59/7	qRT-PCR	Reported	100
Liu	2015	China	75/20	52 (29–82)	Hepatocellular	95	22/73	qRT-PCR	Survival curves	68
He	2013	China	70/42	44 (6–86)	Glioma	112	38/74	qRT-PCR	Survival curves	161
Bovell	2013	USA	170/175	<65 169; ≥ 65 176	Colorectal	345	184/161	qRT-PCR	Reported	348
Schetter	2008	USA	66/18	64.6 (32–87)	Colorectal	84	37/46	qRT-PCR	Reported	141.9
Wang	2013	China	NR	50.2 (30–70)	Ovarian	156	48/108	qRT-PCR	Survival curves	88
Madhavan	2012	Germany	NR	61 (30–92)	Breast	133	104/26	Profiling	Survival curves	10.8
Imaoka	2015	Japan	91/39	68	Gastric	130	69/61	qRT-PCR	Reported	78
Ikenaga	2010	Japan	71/42	66 (36–86)	Pancreatic	113	109/4	qRT-PCR	Survival curves	98
Greither	2010	Germany	NR	NR	Pancreatic	50	NR	qRT-PCR	Survival curves	NR
Nicolai	2012	Denmark	111/114	64 (31–85)	Pancreatic	225	35/180	qRT-PCR	Reported	196
Costa	2011	USA	13/21	NR	Ependymoma	34	22/12	qRT-PCR	Reported	160.8
Mathé a	2009	USA	12/12	<62 11; ≥ 62 13	Esophagus	24	21/3	qRT-PCR	Survival curves	NR
Mathé b	2009	Japan	30/3	<62 14; ≥ 62 19	Esophagus	33	19/14	qRT-PCR	Reported	NR